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Patients with liver cirrhosis can develop hyperammonemia and hepatic encephalopathy
(HE), accompanied by pronounced daytime sleepiness. Previous studies with healthy
volunteers show that experimental increase in blood ammonium levels increases
sleepiness and slows the waking electroencephalogram. As ammonium increases
adenosine levels in vitro, and adenosine is a known regulator of sleep/wake homeostasis,
we hypothesized that the sleepiness-inducing effect of ammonium is mediated by
adenosine. Eight adult male Wistar rats were fed with an ammonium-enriched diet
for 4 weeks; eight rats on standard diet served as controls. Each animal was
implanted with electroencephalography/electromyography (EEG/EMG) electrodes and
a microdialysis probe. Sleep EEG recording and cerebral microdialysis were carried out
at baseline and after 6 h of sleep deprivation. Adenosine and metabolite levels were
measured by high-performance liquid chromatography (HPLC) and targeted LC/MS
metabolomics, respectively. Baseline adenosine and metabolite levels (12 of 16 amino
acids, taurine, t4-hydroxy-proline, and acetylcarnitine) were lower in hyperammonemic
animals, while putrescine was higher. After sleep deprivation, hyperammonemic animals
exhibited a larger increase in adenosine levels, and a number of metabolites showed
a different time-course in the two groups. In both groups the recovery period
was characterized by a significant decrease in wakefulness/increase in NREM and
REM sleep. However, while control animals exhibited a gradual compensatory effect,
hyperammonemic animals showed a significantly shorter recovery phase. In conclusion,
the adenosine/metabolite/EEG response to sleep deprivation was modulated by
hyperammonemia, suggesting that ammonia affects homeostatic sleep regulation and
its metabolic correlates.
Keywords: hyperammonemia, hepatic encephalopathy, sleep homeostasis, adenosine, metabolomics/metabolic
profiling
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INTRODUCTION
Hepatic encephalopathy (HE) is a syndrome of neurological and
psychiatric symptoms which complicates liver cirrhosis. HE is
due to gut-derived neurotoxins, such as ammonia, which escape
hepatic detoxification and reach the brain through the systemic
circulation (Sherlock et al., 1954; Vilstrup et al., 2014). HE is
often observed after upper gastro-intestinal bleeding, because
the blood is ingested and the amino acids absorbed by the
small intestine are rapidly oxidized, with a sharp increase in
ammonium levels. In humans, this situation can be simulated by
oral administration of a mixture of amino acids of comparable
composition to that of hemoglobin (amino acid challenge;
Douglass et al., 2001).
HE patients show excessive daytime somnolence, which has
been connected to elevated ammonium levels (Bersagliere et al.,
2012). We have previously shown that an amino acid challenge
results in increased subjective sleepiness both in healthy
volunteers and in patients with cirrhosis (Bersagliere et al., 2012).
A more detailed EEG analysis showed increased power and
increase in large amplitude waves during waking, compatible
with the self-reported feeling of sleepiness (Bersagliere et al.,
2012). However, while after an amino acid challenge healthy
volunteers slept longer and deeper, patients with cirrhosis, who
are chronically hyperammonemic, seemed unable to convert
sleepiness into restorative, deep sleep (Bersagliere et al., 2012).
The mechanisms by which hyperammonemia induces sleepiness,
and in experimental participants increases sleep, have remained
unexplored. Also the question regarding the difference in the
sleep response between the patients and healthy volunteers has
remained open.
Adenosine is one of the known sleep-inducing molecules,
which is particularly involved in the mediation of sleep
homeostasis (Brown et al., 2012; Porkka-Heiskanen, 2013).
Cerebral levels of extracellular adenosine increase during
wakefulness and decrease during sleep (Porkka-Heiskanen et al.,
1997, 2000), and extracellular levels of adenosine increase in
the basal forebrain during sleep deprivation (Porkka-Heiskanen
et al., 1997). As an acute dose of caffeine, an adenosine receptor
antagonist (Ribeiro and Sebastião, 2010), counteracts the effect
of induced hyperammonemia in healthy volunteers (Casula et al.,
2015), we hypothesized that the sleepiness/sleep-inducing effects
of hyperammonemia are mediated, at least partly, via adenosine.
To test this hypothesis, we measured adenosine levels from
brain microdialysates collected from rats that were made
hyperammonemic and controls during waking, sleep, sleep
deprivation, and recovery sleep.
To further explore the effect of hyperammonemia, we also
measured metabolites in microdialysate from hyperammonemic
and control animals before and after sleep deprivation using a
targeted metabolomics approach (Skene et al., 2017).
METHODS
Adult male Wistar rats (250–280 g) were fed an ammonium-
enriched diet (Felipo et al., 1988) ad libitum for 4 weeks.
A standard diet (Teklad Global 18% Protein Rodent Diet,
Harlan) was mixed with ammonium acetate (20% w/w) and
the appropriate amount of water to produce a homogenous
mixture, which was subsequently air-dried (40◦C for 2–3 days).
Control rats were fed a standard diet prepared following the same
procedure except for the addition of ammonium acetate.
Animals were kept under constant temperature (23–25◦C) on
a 12 h light–12 h dark cycle, with lights on from 09:00 to 21:00 h.
All animal procedures were approved by the University of
Helsinki Ethical Committee for Animal Experiments and by the
Regional Committee of the State Provincial Office and performed
according to applicable national and European Union legislation.
Ammonia Levels
Fasting (3–4 h) capillary ammonia concentrations weremeasured
during the fourth week using an Ammonia Checker (Menarini
Diagnostics, Firenze, Italy). The pre-warmed foot was punctured
with a 25G needle, 20µl of blood obtained via a capillary tube and
transferred to an ad hoc reagent strip. Ammonia concentrations
were then determined by a reflectance meter (Huizenga et al.,
1995).
Surgery
Animals were habituated to handling at least 4 days prior
to surgery, which was performed during the fourth week.
Under general anesthesia, they were implanted with
electroencephalography/electromyography (EEG/EMG)
electrodes and a microdialysis guide cannula. They were
anesthetized with isoflurane (IsoFlo R©Vet 100%, Abbott
Laboratories Ltd, England) (5% induction, 2% maintenance)
and placed in a stereotaxic device. Before the surgery they were
injected with buprenorphine (Temgesic R©, Indivior UK Limited,
Slough, UK, 0.05 mg/kg, s.c.). After exposing, cleaning and
disinfecting the skull bone, two gold-coated screws were fitted
into the skull for frontal-parietal epidural bipolar recording of
the EEG, while two silver wire electrodes were inserted into the
neck muscles for EMG recording. A unilateral guide cannula
(CMA11 Guide Cannula; CMA/Microdialysis, Stockholm,
Sweden) was implanted targeting the basal forebrain cholinergic
area (Porkka-Heiskanen et al., 2000) for subsequent insertion of
the microdialysis probe. Electrodes and guide cannula were fixed
to the skull with acrylic dental cement. After surgery, animals
were individually housed in open Plexiglas boxes, connected
to the recording cables through swivels allowing them to move
freely. Rats were left for adaptation and recovery for at least 5
days.
In vivo Microdialysis and EEG/EMG
Recording
Each rat underwent adenosine sample collection by in vivo
microdialysis, and EEG/EMG recording during three consecutive
days [pre-baseline (pre-BL), baseline (BL), and sleep deprivation
(SD) day] (Figure 1). A microdialysis probe (CMA11
Microdialysis probe; 14 mm shaft length, 2 mm dialyzing
membrane length, 0.24 mm diameter; CMA/Microdialysis) was
inserted through the guide cannula into the basal forebrain
(Porkka-Heiskanen et al., 2000) and inlet and outlet tubing
(1.5m pieces of fluorinated ethylene propylene tubing;
Frontiers in Physiology | www.frontiersin.org 2 August 2017 | Volume 8 | Article 636
Marini et al. Ammonia and Homeostatic Sleep Regulation
FIGURE 1 | Study design and timing of experimental procedures on each study day.
CMA/Microdialysis) connected to the probe the day before
the beginning of the experiment. Artificial cerebrospinal fluid
(NaCl 147 mM, KCl 3 mM, CaCl2 1.2 mM, MgCl2 1 mM, pH
7.2) was continuously perfused at a flow rate of 1 µl/min. Thirty
minute dialysate samples were automatically collected for 11 h
during the light period from 09:30 to 20:30 h and stored at
−20◦C.1.
EEG/EMG recordings were sampled at 277.78 Hz with a
resolution of 8 mV/bit. Signals were amplified (gain EEG:
5,000; EMG: 2,000), analogically filtered (EEG: 0.3 Hz high-
pass, 100 Hz low-pass; EMG: 10 Hz high-pass, 100 Hz low-
pass), monitored on-line during the experiments and stored on a
computer equipped with the Spike 2 software (version 5.19; CED,
Cambridge, UK) for off-line analysis.
Sleep Deprivation
On the third day, animals were sleep-deprived for 6 h, starting
at 11:00 h (Figure 1), by gentle handling (Franken et al., 1991),
which includes presentation of new objects into the cage and
tactile stimulation, such as light touches of a brush/hand.
After sleep deprivation, microdialysis sampling and EEG/EMG
recording were continued and animals left undisturbed to allow
for recovery sleep (Figure 1).
Probe Tips Location
At the end of the recovery period, rats were sacrificed with a
lethal dose of pentobarbital (Mebunat 60 mg/kg). The location
of the tips of the probes was marked by injecting color ink
through a modified microdialysis probe. Brains were removed
and immediately frozen. Twenty micrometer coronal sections
were cut using a cryostat, mounted on a glass plate and stained
with toluidine blue. The location of each probe was verified by
visual inspection under a light microscope, using a rat brain
atlas (Paxinos and Watson, 1998). Only those rats with probe
locations in the close vicinity of the target area, including
the horizontal diagonal band of Broca, substantia innominata,
magnocellular preoptic area, lateral preoptic area and the basal
nucleus of Meynert, were included in subsequent analyses
(Figure 2).
Adenosine Measurement
The dialysate samples were analyzed with a microbore high-
performance liquid chromatography (HPLC) system coupled to
a fluorescent detector (Waters 2,475), as previously described
(Kalinchuk et al., 2015). The mobile phase, consisting of
ammonium acetate 50 mM, tetrabutyl-ammonium hydrogen
sulfate 0.2 mM, EDTA 1 mM in 15% of MeOH, pH 5.6, was
passed through the column at a flow rate of 1 ml/min. Ten
microliters of the first 30 min sample of every hour from BL
and SD days were injected through a Kinetex R© C18 column
(100A, 150 × 4.60 mm, particle size: 5 micron, Phenomenex,
USA), coupled with a pre-column (KJO-4282, Phenomenex,
USA). Adenosine was detected at a wavelength of 460 nm and its
concentrations were determined by comparing sample peak areas
with those of standards (AMP, adenosine, cAMP, cdAMP, Sigma-
Aldrich) using LabSolutions software (Shimadzu). Detection
limit: 0.1 nM; linear range of the assay: 0.1–50 nM; coefficient
of variation < 10%. Any outliers were determined and treated
according to a modified Thompson tau Method.
One of themain features of this microdialysis technique is that
the sample is collected through a membrane, which cannot be
penetrated by large molecules, i.e., enzymes (Porkka-Heiskanen
et al., 1997). Thus, the degradation of adenosine in the collected
microdialysis samples is completely dependent on the stability
of the molecular structure, not on the degrading enzymes (as
opposed to what happens in tissue samples, where adenosine is
instantly metabolized). The recovery rate of adenosine, measured
from known concentrations of adenosine solutions, is of the
order of 10%, depending on flow rate, membrane, temperature
and the concentration of the original solution.
Targeted LC/MS Metabolomics
A subset of the dialysate samples (n = 69) were analyzed
in 5 control and 5 hyperammonaemic animals using the
AbsoluteIDQ R© p180 targeted metabolomics kit (Biocrates Life
Sciences AG, Innsbruck, Austria) on a Waters Xevo TQ-S mass
spectrometer (MS) coupled to an Acquity UPLC system (Waters
Corporation, Milford, MA, USA; Davies et al., 2014). We took
two samples per each animal during BL day: one at ZT3.5 and
another one at ZT8, which correspond to the time points of
beginning and middle of SD during SD days. This was done to
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FIGURE 2 | Coronal brain sections (modified from Paxinos and Watson, 1998) with black spots marking the location of the microdialysis probe tips. All probe tips
were located between anterior-posterior levels of +20 and −92 mm with respect to bregma. Target areas include: horizontal diagonal band of Broca (HDB), substantia
innominata (SI), magnocellular preoptic area (MCPO), lateral preoptic area (LPO) and the basal nucleus of Meynert (B). The location of probes with tips outside the
target area are not shown, and the corresponding rats (n = 2, both on the ammonia-enriched diet) were excluded from the analysis.
evaluate metabolites during SD (i.e., BL vs. SD analysis). Then we
took three samples per each animal during SD: at ZT4, ZT5.5 and
ZT7.5. These correspond to the beginning (2 h after beginning
of SD when, according to our experience, changes start to occur,
i.e., adenosine rise), middle and the end of the SD. Finally, two
samples of recovery period were taken from each animal: at ZT8.5
and ZT9.5 to evaluate metabolites immediately after finishing
SD (during the first hour of recovery), and later on, closer to
the end of light period. The dialysate samples (10 µl) were
prepared according to the manufacturer’s instructions adding
several stable isotope–labeled standards to the samples prior
to derivatisation and extraction. Sample order was randomized
and all samples were run on a single 96-well plate including 3
levels of quality controls. Up to 183 metabolites from 5 different
compound classes (acylcarnitines, amino acids, biogenic amines,
glycerophospholipids and sphingolipids) can be quantified using
either LC/MS or flow injection analysis/MS. Metabolites were
selected if the % valid or % semiquantitative values were above
60% (average 76%). In addition, putrescine (35%), acetylcarnitine
(C2) (40%), DOPA (46%), and SDMA (49%) were included
since their values were above zero but below the lower limit of
quantification.
Sleep-Wake Scoring
All EEG traces were digitally high-pass filtered (1.4 Hz cut-
off). EEG recordings were then semi-automatically scored in 4 s
epochs using AUTOSCORE script, version 1.7 (Rytkönen et al.,
2011) and manually checked using the SLEEPSCORE script,
version 1.01 (CED). Vigilance states were scored according to
standard criteria (Kalinchuk et al., 2015). Briefly, NREM sleep
was recognized by high-amplitude EEG associated with slow
waves in the delta range (0.5–4 Hz) and low-voltage EMG; REM
sleep was recognized by low-amplitude, high-frequency EEG
associated with the absence of EMG except for whiskers and ears
twitches, as well as EEG theta activity (4–9 Hz); wakefulness was
recognized as low-amplitude, high-frequency EEG activity with
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high-voltage EMG. The time spent in wake/NREM/REM was
calculated over the total recording time of BL day, and hourly
values compared between the two groups. The number of state-
specific bouts per hour and the bout length distribution over the
24-h BL day were also obtained. State-specific time during the 16
h of recovery of the SD day were compared to the corresponding
values at baseline, on an hourly basis.
Statistical Analysis
Data are presented as means ± SD or SEM. Baseline
ammonia and point adenosine/metabolite values were compared
by the Student t or Mann-Whitney U-test, as appropriate.
Baseline adenosine/metabolite values and differences between
post-sleep deprivation and baseline values were analyzed
by repeated measures ANOVA (factors: time and group);
p-values were corrected for multiple comparisons. Differences
(sleep deprivation-baseline) were chosen over ratios (sleep
deprivation/baseline) because of the presence of zero values
for wake/NREM/REM in several time bins. Empty cells, if
any, were treated by standard missing values replacement and
analyses were performed both prior to (missing out the pertinent
time points) and after replacement. Multivariate analysis of
the metabolite data was performed by principal component
analysis (PCA) and orthogonal partial least squares discriminant
analysis (OPLS-DA) validated by permutation testing (p≤ 0.05),
using SIMCA-P v12.0 software (Umetrics, Sweden). Differences
in individual metabolite levels were analyzed in R version
3.1.2 using the linear models and ANOVA methods in the
stats package. Linear models were fitted to the group (control
or ammonia treated) and time (n = 7), with the animal
as covariate. Significant differences for group, time and their
interaction were determined using 2-way ANOVA. P-values
were corrected for multiple comparisons according to the
Benjamini-Hochberg False Discovery Rate (FDR). Metabolites
were considered significant at a FDR cut off <0.05. For testing
statistical significance, missing values were not taken into
account.
RESULTS
Capillary ammonia levels were significantly higher in the
modified diet compared to the control group (73 ± 25 vs. 42
± 15 µg/dl, p = 0.02), confirming that the diet had produced
the expected results. Rats fed the ammonium-enriched diet
tended to gain less weight compared to control animals over the
treatment period and while the group factor was not significant,
an interaction was detected between group and time (time: F =
74.9, p < 0.001; group: F = 1.3, p= 0.271; time∗group: F = 8.5, p
< 0.001). Post-hoc comparisons were not significant at any time
point; actual weights from week 2, when the two groups started
to diverge, were as follows (mean ± SD; standard vs. ammonia-
enriched diet): 392± 34 vs. 369± 34 at week 2; 411± 28 vs. 381
± 28 at week 3; 420± 23 vs. 387± 20 at week 4.
Spontaneous Sleep-Wake Cycle
Control and hyperammonemic rats spent comparable periods
of time in wakefulness, NREM and REM sleep (Figure 3A).
Similar state-specific time distributions over the 24 h were
FIGURE 3 | (A) Comparison of the total time (min) spent in Wake-NREM-REM
state, in the light (left) and dark (right) period, between control (white bars) and
hyperammonemic (black bars) animals, during the spontaneous sleep-wake
cycle. (B) Comparison of Wakefulness, NREM and REM sleep profile
(min/hour) between control (circles) and hyperammonemic (triangles) animals,
during the spontaneous sleep-wake cycle.
observed, with slight variations, particularly in REM sleep
(Figure 3B). However, these did not impinge on total REM
sleep time. The number of state-specific bouts per h and
their length distribution were also comparable in control and
hyperammonemic rats.
Sleep Deprivation-Induced Recovery Sleep
Following sleep deprivation, a significant decrease in wakefulness
and increase in NREM and REM sleep compared to baseline
values was observed in both groups [Figure 4 (n = 8
control and n = 6 hyperammonaemic animals) and Figure 5].
Direct comparisons of the sleep time increase/wakefulness
decrease showed similar average values in the control and
hyperammonemia groups [wakefulness: −151 ± 9 min (−26%)
vs. −142 ± 14 min (−24%); NREM: 105 ± 6 min (+35%) vs.
97 ± 9 min (+33%); REM: 46 ± 4 min (+58%) vs. 46 ± 6 min
(+60%)].
In a more detailed analysis, the differences between baseline
and experimental day values were compared separately for each
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FIGURE 4 | Hourly distribution of the time (minutes; mean ± SEM) spent in Wakefulness/NREM/REM at baseline (open symbols) and during the recovery period
(closed symbols) in control (A; n = 8, circles) and hyperammonemic rats (B; n = 6, triangles). Analysis of recovery was performed on both the 9–16 h (gray portion of
the graphs) and 9–24 h intervals. Statistical analysis of wakefulness, NREM and REM (presented in Table 1), was performed by comparing the differences between
baseline and sleep deprivation in the control group (A) as well as baseline and sleep deprivation in the ammonium-treated group (B) [repeated measures ANOVA of
the mathematical difference between baseline and recovery (in minutes), by group; Table 1].
TABLE 1 | Statistical analysis of differences between baseline and recovery sleep in wakefulness, NREM and REM sleep in controls and in ammonium-treated animals
over two time intervals: 9–16 and 9–24 h.
Recovery 9–16 h Recovery 9–24 h
F p Post-hoc (significant time points) F p Post-hoc (significant time points)
Wakefulness Time 2.9 0.008 / 2.3 0.005 /
Group 9.4 0.010 0.3 0.572
Time*group 1.8 0.091 1.5 0.093
NREM Time 3.9 0.001 13, 14, 15 2.7 0.001 /
Group 8.8 0.012 0.7 0.414
Time*group 1.3 0.252 1.4 0.134
REM Time 2.6 0.019 11, 13, 16 2.1 0.011 17
Group 3.0 0.105 0.0 0.978
Time*group 2.1 0.057 1.5 0.101
Results of repeated measures ANOVA of the mathematical difference between baseline and recovery (in minutes), by group; post-hoc: Tukey test. See also Figure 4. Bold typeface
marks significant p-values.
vigilance state in both control and hyperammonemic rats. This
analysis revealed that the control animals exhibited a normal
NREM recovery phase, lasting approximately 9 h with a gradual
decline in time spent in NREM sleep (Figure 4A), while in
hyperammonemic animals the primary recovery phase was
shorter (as demonstrated by the statistical analysis described in
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FIGURE 5 | (A) Decrease in Wakefulness time (min) and increase in NREM and REM sleep time after sleep deprivation (9–16 h, black bars) with respect to baseline
(white bars), in control (left) and hyperammonemic (right) animals. (B) Comparison of the differences (recovery minus baseline, 9–16 h) in Wakefulness, NREM and
REM sleep time (min) between control (white bars) and hyperammonemic (black bars) animals.
Table 1), lasting only about 5 h (Figure 4B). In the first part of the
recovery phase (h 9–16), the hyperammonemic animals exhibited
significantly more wakefulness and less NREM sleep compared to
the control animals (Table 1).
NREM Bout Duration during Recovery Sleep
Both control and hyperammonemic animals showed a
significant increase in the duration of NREM bouts after
sleep deprivation. The increase, however, was slightly lower in
the hyperammonemia group compared to the controls [20 ± 3 s
(+32%) vs. 26 ± 3 s (+43%)]. Higher time-resolution analysis
showed a more pronounced increase in NREM bout duration in
the first 4 h in both groups [hyperammonemia: 86± 15 s (158%);
control: 88 ± 8 s (150%)]. In the control group, the increase was
still present, albeit less pronounced, in the subsequent time-bin
(4–8 h), while in the hyperammonemic rats the values dropped
sharply to baseline.
Adenosine
Out of 300 samples, 28 were lost for adenosine measurement.
Average adenosine levels were lower (although not significantly
lower) in hyperammonaemic compared to control animals at
baseline (0.500 ± 0.064 nM vs. 0.683 ± 0.103 nM). Average
adenosine levels rose during sleep deprivation, reaching similar
values in hyperammonaemic and control animals (0.688 ±
0.103 nM vs. 0.740 ± 0.095 nM). Thus, the adenosine response
to sleep deprivation was significantly greater and longer in
hyperammonemic compared to control animals (Figure 6; time:
F = 2.4, p = 0.012; group: F = 4.9, p = 0.047; time∗group: F =
0.5, p= 0.829).
Metabolites
Some metabolites were detectable (28 of 183, 15%) in the
brain dialysate using targeted LC/MS metabolomics, largely
comprising amino acids (n = 16) and biogenic amines (n = 8).
PCA of the 28 metabolites showed a clear distinction between
hyperammonemic (n = 5) and control animals (n = 5) in PC1
[amount of variance in the × matrix explained by PC1 (R2X)
(cumulative) = 0.440, estimate of the predictive ability of the
model (Q2) (cumulative) = 0.376]. A plot showing the mean
score on PC1 (± SEM) for each sampling time point (n =
7) for the controls and hyperammonemic animals separately
(n = 5 for both groups) is presented in Figure 7A. A clear
difference between the controls and hyperammonemic animals
across the time course (baseline; during sleep deprivation; after
sleep deprivation) was observed. OPLS-DA models, validated
by permutation analysis, showed separation between the control
and hyperammonemic rats (Figure 7B). The p(corr) loading plot
(Figure 7C) showed reduced concentrations of all of the amino
acids (n = 16) except glutamate, as well as decreased taurine, t4-
hydroxy-proline and acetylcarnitine levels in hyperammonemic
animals. By contrast, putrescine and glutamate concentrations
were higher in hyperammonemic animals. ANOVA analyses
of the metabolite concentrations showed significantly reduced
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FIGURE 6 | Differences in adenosine levels (sleep deprivation – baseline, with sleep deprivation starting at 11 h; mean ± 95% confidence interval) over time, in control
(gray circles) and hyperammonemic (black squares) animals. time: F = 2.4, p = 0.012; group: F = 4.9, p = 0.047; time*group: F = 0.5, p = 0.829.
levels of 12 amino acids (alanine, arginine, glutamine, lysine,
methionine, ornithine, phenylalanine, proline, serine, threonine,
tyrosine, valine), taurine, t4-hydroxy-proline and acetylcarnitine
in the hyperammonemic animals (FDR-adjusted p < 0.05). Only
putrescine (FDR-adjusted p = 5.2E-10) and glutamate (FDR-
adjusted p = 0.07) showed increased dialysate levels in the
hyperammonemic animals compared to the controls. Of the
28 metabolites measured, only putrescine showed a significant
group∗time interaction. The p(corr) values for the OPLS-DA
model are presented in Table 2.
For each animal used for the targeted metabolomics analysis
(n= 5 in each group), seven time series samples were analyzed [2
at BL 3.5 and 8.0 ZT (Zeitgeber Time); 3 during SD 4.0, 5.5 and
7.5 ZT and 2 during recovery (R) following SD 8.5 and 9.5 ZT].
Figure 8 presents the mean (±SEM) concentrations of the 28
metabolites at BL, SD, and R in the control and hyperammonemic
animals. Analyses comparing dialysate metabolite levels at BL,
SD, and R revealed fewer significant differences, partly because
of low sample number/samples below the limit of detection. As
a result, the metabolites arginine, glutamate, glycine, histidine,
phenylalanine, proline, serine, tryptophan, tyrosine, DOPA, and
SDMA could not be analyzed.
Significant changes over time in relation to the different
conditions (baseline/sleep deprivation/recovery) were observed
for the metabolites acetylcarnitine, t4-hydroxyproline, PC ae
30:1 and carnosine (Figure 8). In addition, while glutamine
and methionine increased during sleep deprivation in control
animals, they did not in hyperammonemic animals (Figure 8).
DISCUSSION
The main findings of the present work were that prolonged
hyperammonemia resulted in a tendency to decreased brain
adenosine levels under a spontaneous sleep-wake cycle, whereas
sleep deprivation increased basal forebrain adenosine levels
more pronouncedly in hyperammonemic rats. In spite of the
large increase in adenosine levels during sleep deprivation, the
recovery sleep response was less efficient than normal, i.e., both
shorter and more fragmented in the hyperammonemic animals.
The effects of increased ammonium levels on physiological
functions are critically dependent on the dose and duration
of the exposure (Felipo and Butterworth, 2002). Bjerring
et al. (2015) have reported that rat brain slices exposed
to ammonia exhibit a rapid increase in adenosine, with a
linear dose-response correlation, while in the present study,
basal forebrain adenosine levels were decreased under chronic
hyperammonemia conditions. Increased ammonium levels have
a multitude of effects on brain functions. As detoxification of
ammonium takes place predominantly by astrocytes through
glutamine synthesis, astrocyte swelling, changes in astrocyte
morphology and expression of astrocyte proteins are frequent
findings in hyperammonemia (Butterworth, 2010). Chronic
hyperammonemia downregulates functional NMDA receptors
and impairs NMDA-receptor-associated signal transduction
pathways (Felipo and Butterworth, 2002), presumably decreasing
NMDA-mediated neural activation. This tends to decrease energy
consumption, which could at least partly explain the decreased
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FIGURE 7 | (A) Principal component analysis (PCA) of all the metabolite data
(n = 28 metabolites). The change in mean score (±SEM) on PC1 in the control
(n = 5, closed circles) and hyperammonemic animals (n = 5, open circles)
across the time course (baseline, purple; during sleep deprivation, white; after
sleep deprivation, orange) is shown. (B) Orthogonal partial least squares
discriminant analysis (OPLS-DA) model showing separation by condition [Q2
(cumulative) = 0.575, R2X (cumulative) = 0.493; R2Y (cumulative) = 0.651].
Each animal is color coded; triangles represent control animals; circles
represent hyperammonemic animals. (C) OPLS-DA p(corr) loading plot of
control vs. hyperammonemic animals. Negative p(corr) values represent
decreased and positive p(corr) values represent increased metabolite
concentrations in hyperammonemic animals compared to controls. The
metabolite bars are color coded according to metabolite class as follows:
amino acids and biogenic amines (blue); acylcarnitines (green);
phosphatidylcholine acyl-akyl (PC ae) (light orange); sphingolipids (SM) (brown).
adenosine levels during the spontaneous sleep-wake cycle in
hyperammonemic animals.
Sleep deprivation increases adenosine levels in the basal
forebrain of rats, which has been suggested to be one of
TABLE 2 | OPLS-DA loadings p(corr) values of the measured metabolites in
models comparing controls with hyperammonemic animals.
Metabolite p(corr)
Lys −0.805
Gln −0.791
Thr −0.758
Met −0.719
Taurine −0.693
Tyr −0.655
t4-OH-Pro −0.620
Arg −0.558
Pro −0.554
Phe −0.554
Ser −0.541
Val −0.534
C2 −0.522
Ala −0.507
SDMA −0.504
DOPA −0.334
Trp −0.311
Gly −0.297
Orn −0.295
His −0.219
Creatinine −0.100
Carnosine −0.092
Serotonin 0.148
PC ae C30:1 0.152
SM (OH) C22:1 0.235
SM (OH) C22:2 0.280
Glu 0.437
Putrescine 0.578
the mechanism of sleep homeostasis (Porkka-Heiskanen et al.,
1997). In the present study, the basal forebrain adenosine levels
were increased during sleep deprivation in both control and
hyperammonemic animals, the increase being larger in the
hyperammonemic rats. However, while the control rats exhibited
a normal, consolidated increase in slow wave sleep during
recovery sleep, the recovery sleep response was shorter and more
fragmented in the hyperammonemic rats, indicating that the
adenosine response was not translated into a normal recovery
sleep response.
Interestingly, chronic hyperammonemia decreases NMDA-
mediated signal transduction through the NO-cGMP pathway,
evidently by inhibiting the step by which NO increases cGMP
(Felipo and Butterworth, 2002). During sleep deprivation,
NO levels are increased (Kalinchuk et al., 2010). The large
increase in adenosine levels in hyperammonemic animals
during sleep deprivation, in spite of low levels during
spontaneous sleep, could possibly be explained by the sleep
deprivation-induced increase in NO levels in the basal
forebrain.
Acute exposure of brain slides to ammonia rapidly increases
adenosine (Bjerring et al., 2015). In the same study, in vivo
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FIGURE 8 | Concentrations (mean ± SEM) of the 28 metabolites at baseline (BL), sleep deprivation (SD) and recovery (R) in control (white) and hyperammonemic
(black) animals. Metabolites are presented by class: (A) Amino acids and Biogenic Amines, (B) Acylcarnitines, (C) Phosphatidylcoline acyl-akyl, and (D) Sphingolipids.
recordings showed a tendency toward increased adenosine
levels in rats with hyperammonemia and systemic inflammation
compared to a control group (Bjerring et al., 2015). Our
in vivo findings, over a longer period of time and defined
sleep-wake conditions, suggest that chronic hyperammonemia
results in enhanced, immediate adenosine release in response
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to sleep deprivation. This observation could explain a
number of our previous observations in healthy volunteers
with acute hyperammonemia, namely the increase in their
subjective sleepiness (Bersagliere et al., 2012), slowing of their
reaction times (Casula et al., 2015), and the deeper/longer
subsequent sleep episode (Bersagliere et al., 2012). Effects
in patients with cirrhosis were slightly different in response
to the same stimulus (Bersagliere et al., 2012, 2013), most
likely because induced hyperammonemia in cirrhosis is
acute-on-chronic, with a mixture of immediate and adaptive
effects.
Adenosine exerts its sleep promoting action mainly through
binding to the A1 receptor (Halassa et al., 2009). Previous
studies have demonstrated that mRNA levels of A1 adenosine
receptor in the basal forebrain are up-regulated during sleep
deprivation (Basheer et al., 2000) and are inhibited by an
antisense oligonucleotide, or by a conditional knockout, resulting
in an attenuated compensatory increase in NREM sleep time
and slow wave activity (Thakkar et al., 2003; Bjorness et al.,
2009). Functional imaging studies in cirrhotic patients have
documented a decrease in cerebral levels of the A1 adenosine
receptor (Boy et al., 2008).
Hyperammonemia did not affect baseline sleep
time/architecture to any significant extent, at least over a 4-
week period. This is in line with the results obtained by Llansola
et al. (2012), who observed a decrease in REM sleep time only
after 7 weeks of an ammonia-enriched diet. Analysis of the
post-sleep deprivation recovery sleep highlighted a significant
increase in NREM sleep time/decrease in wakefulness in both
groups. However, in hyperammonemic animals the recovery
sleep response was much shorter, in spite of the larger increase in
adenosine levels. Similar impairment in generating restful sleep
has been observed in cirrhotic patients after the acute induction
of hyperammonemia (Bersagliere et al., 2012).
In an attempt to study the metabolic processes underlying
central hyperammonemia and adenosine/sleep deprivation
interactions, multiple metabolites were measured in the brain
dialysate. All but one (glutamate) of the 16 amino acids had
reduced dialysate levels in hyperammonemic animals. These
abnormalities could reflect a number of processes, including
impaired amino acid synthesis, increased catabolism or defective
transport mechanisms, most likely involving different cell types
(Benjamin and Quastel, 1975). An increase in extracellular
glutamate content has been documented using different models
of hyperammonemia/HE (Monfort et al., 2002), confirming that
impaired glutamatergic neurotransmission contributes to the
pathophysiology of the syndrome. It has been suggested that
glutamatemay act both as a nitrogen and energy buffer within the
brain, thus its alterations may also be linked to those observed in
the amino acids dialysate content.
Previously published literature mostly documents
abnormalities in the levels of the branched chain amino
acids (Soeters and Fischer, 1976; Tajiri and Shimizu, 2013), while
we observed a reduction of virtually all amino acids measured.
This may relate to the notion that chronic hyperammonemia
results in brain atrophy, which may be mediated by disturbed
protein synthesis/regeneration due to insufficient amino acid
availability (Amodio et al., 2003; Garcia-Martinez et al., 2011).
Our findings may have been confounded, to some extent, by
the fact that animals fed the ammonia-enriched diet most
likely ate less, and tended to grow less. This may also explain
the discrepancy between the reduction of virtually all amino
acids observed here and previous experimental (Okada et al.,
2009) and clinical studies (Schmidt et al., 2004), especially in
relation to glutamine, which has generally been observed to
increase after exposure to ammonia. Insufficient amino acid
availability may also affect the range of potential amino acid
modulation in response to sleep deprivation/recovery, thus
explaining the flat profiles observed in the hyperammonemic
animals in this study. Our novel, preliminary findings also
suggest that targeted metabolic profiling of brain dialysate offers
promise to study brain amino acid metabolism in sleep-wake
regulation.
A broader understanding of the underlying mechanisms
could have been obtained if plasma metabolomics data were
available, which is a limitation of our study. It should also be
remembered that the model used in this study is a model of
pure hyperammonemia (on healthy liver), thus some of the
changes in protein metabolism due to hyperammonemia plus
liver failure may not be present. On the other hand, the metabolic
and sleep-wake effects observed solely by changing dietary
ammonia are striking, and confirm that even in the absence of
hepatic failure, hyperammonemia affects cerebral metabolism,
neurotransmission and sleep-wake cycles. Hyperammonemic
animals also had significantly reduced taurine, t4-hydroxy-
proline and acetylcarnitine levels in their brain dialysate.
A reduction in taurine was also recently observed in the
cerebrospinal fluid of patients with hepatic failure and HE,
while acetylcarnitine levels were increased (Weiss et al., 2016).
Again, the discrepancy may be related to the presence of
hepatic failure in the human study and its absence in our
model.
Only putrescine was significantly increased in the brain
dialysate of hyperammonemic animals. Increases in putrescine
have been previously reported, for example, in the cerebrospinal
fluid of a rat model of multiple sclerosis (Noga et al.,
2012). In our model putrescine may be a correlate of either
neuroinflammation (Rodrigo et al., 2010) or blood brain
barrier alterations (Skowron´ska and Albrecht, 2012). Of interest,
putrescine increased further when hyperammonemic animals
were sleep deprived. This finding suggests that the association
of hyperammonemia and insomnia, which are both common in
cirrhosis, may have more than additive effects.
In conclusion, hyperammonemia modulates the
adenosine/metabolite/EEG response to sleep deprivation.
These observations fit with both the excessive sleepiness and
fragmented sleep exhibited by hyperammonemic patients.
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